OJQ

Cardiac Allograft Gene Expression Profiling Test System

Product code
OJQ
Device name
Cardiac Allograft Gene Expression Profiling Test System
Device class
Class 2
21 CFR
21 CFR 862.1163
Medical specialty
Cardiovascular
Marketing pathway
510(K)
510(k) clearances (last 3 years)
1
Summaries archived here
1 (direct download)
510(k) clearances (all years, FDA)
2 (all years; only the last 3 years are listed here)

FDA classification definition

In vitro diagnostic multivariate index assay (ivdmia) test service, performed in a single laboratory, for assessing the gene expression profile of rna isolated from peripheral blood mononuclear cells (pbmc) and indicated for use to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection (acr) at the time of testing in conjunction with standard clinical assessment.

Definition text from the FDA device classification database (U.S. federal government work, public domain).

510(k) clearances, last 3 years (1)

Last three years. Most recent: 2023-09-13.

NumberDecision dateApplicantDevice nameSummary
K2216402023-09-13Caredx, Inc.AlloMap Heart Molecular Expression TestingPDF

1 summaries are archived here for direct download.

Official FDA classification page: OJQ
Classification and pathway per current FDA publications. Data from openFDA (CC0).